Retatrutide, developed by Soma Pharmaceuticals , is attracting increasing attention as a novel method for weight management . This unique medication merges the activity of a GLP-1 receptor stimulant and a GIP receptor activator , aiming to effectively promote weight loss but also target underlying metabolic factors. Early human data have indicated